Ueda Nobuhiko, Noda Takashi, Kusano Kengo, Yasuda Satoshi, Kurita Takashi, Shimizu Wataru
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
JACC Asia. 2023 Apr 25;3(3):335-345. doi: 10.1016/j.jacasi.2023.02.004. eCollection 2023 Jun.
The effectiveness of primary prevention implantable cardioverter-defibrillators (ICDs) is well established. However, there are several unsolved problems related to ICD use for primary prevention in Asia, including ICD underuse, population differences in underlying heart disease, and the rate of appropriate ICD therapy compared with Western countries. Although the prevalence of ischemic cardiomyopathy in Asia is lower than in Europe and the United States, the mortality rate of Asian patients with ischemic heart disease has been increasing recently. As for the use of ICDs for primary prevention, there have been no randomized clinical trials, and limited data are available in Asia. This review focuses on the unmet needs related to ICD use for primary prevention in Asia.
一级预防植入式心脏复律除颤器（ICD）的有效性已得到充分证实。然而，在亚洲，ICD用于一级预防存在几个尚未解决的问题，包括ICD使用不足、潜在心脏病的人群差异以及与西方国家相比适当ICD治疗的发生率。尽管亚洲缺血性心肌病的患病率低于欧洲和美国，但亚洲缺血性心脏病患者的死亡率最近一直在上升。至于ICD用于一级预防，目前尚无随机临床试验，亚洲的相关数据也有限。本综述重点关注亚洲ICD用于一级预防方面未满足的需求。
